The global plasma derived therapy market size accounted for USD 19.68 billion in 2022 and is estimated to achieve a market size of USD 19.68 billion by 2032 growing at a CAGR of 7.8% from 2023 to 2032.
Key Pointers:
Increasing prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), von Willebrand disease, and others are one of the major factors contributing to the business growth across the globe.
According to the report published by the Centres for Disease Control and Prevention in 2022, around 4.2 million people in U.S. suffer from von Willebrand disease. Hence, the availability of effective plasma derived therapy that offers effective solution against these rare diseases will lead to unprecedented growth opportunities to the plasma derived therapy market in the forthcoming years.
The incidence of coronavirus infection has affected millions of individuals worldwide that had temporarily impacted the plasma donation globally, also affected the plasma derived therapy market. However, due to unavailability of specific treatment medicine and vaccine against COVID-19, research institutes have focused on plasma-based therapy to identify any role in treating the COVID-19.
Further, in March 2020, the Houston Methodist Hospital, U.S., announced use of plasma fractionation for treatment of COVID-19 and became the first hospital in U.S. to offer plasma derived therapy among COVID-19 patients. Therefore, high incidence rate of COVID-19 patients has resulted in increased demand for plasma derived immunoglobulins.
Plasma derived therapy is effective treatment derived from human plasma and widely used for the treatment of rare and complex diseases. Plasma-derived therapies help to replace deficient or missing proteins that allow people to lead more healthy and productive lives. The plasma-derived products majorly include coagulation factors, albumin and immunoglobulins that are used as life-saving therapeutics to treat several genetic, and life-threatening diseases globally.
Plasma industry is continuously investing in research and development activities to develop new plasma therapies leading to innovative treatments benefitting the patients. For instance, in March 2016, Grifols had invested USD 360 million in order to expand their production capabilities for plasma-derived therapies. This investment has helped company to enhance its place in the market coupled with its plasma fractionation capacity and purification facility.
Moreover, several other pharmaceutical and biotechnology companies had significant investment towards research and development to develop convalescent plasma therapy to treat critically ill COVID-19 patients. Additionally, favourable regulatory support to develop and commercialize plasma derived therapy is another factor benefiting the market growth. Thus, the aforementioned factors primarily drive the plasma derived therapy market share in 2022.
North America plasma derived therapy market held over 54% business share in 2022 and is projected to experience remarkable growth during the foreseeable future. Favourable government initiatives and expanding coverage of plasma collection centres by leading market players will offer growth opportunities to the market. Furthermore, increasing awareness about plasma derived therapies among blood donors, and favourable initiatives undertaken by major market players to stimulate blood donation in the region will accelerate the regional revenue growth.
Adding to this, U.S. market dominated the North America plasma derived therapy industry in 2022 with significant demand as well as high plasma volume in the region. Increase in number of patients with rare diseases has strengthened the growth potential of market players operating in the country.
Plasma Derived Therapy Market Segmentation
By Product | By Application |
Immunoglobulin Coagulation factors Albumin Others |
Hemophilia Primary immunodeficiency disease Idiopathic thrombocytopenic purpura Others |
Plasma Derived Therapy Market Key Players And Regions
Companies Profiled | Regions Covered |
CSL Behring Takeda Pharmaceutical Company Limited BPL ADMA Biologics Biotest AG Octapharma Grifols Kamada Pharmaceuticals SK Plasma SA Kedrion Pfizer |
North America Europe Asia-Pacific Latin America Middle East & Africa (MEA)
|
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Plasma Derived Therapy Market
5.1. COVID-19 Landscape: Plasma Derived Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Plasma Derived Therapy Market, By Product
8.1. Plasma Derived Therapy Market, by Product, 2022-2030
8.1.1. Immunoglobulin
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Coagulation factors
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Albumin
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Plasma Derived Therapy Market, By Application
9.1. Plasma Derived Therapy Market, by Application, 2022-2030
9.1.1. Hemophilia
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Primary immunodeficiency disease
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Idiopathic thrombocytopenic purpura
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Plasma Derived Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
Chapter 11. Company Profiles
11.1. CSL Behring
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Takeda Pharmaceutical Company Limited
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. BPL
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. ADMA Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Biotest AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Octapharma
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Grifols
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Kamada Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. SK Plasma
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. SA
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms